Revenue: As of FY2025 Q3, the actual value is USD 351 K.EPS: As of FY2025 Q3, the actual value is USD 0.94.EBIT: As of FY2025 Q3, the actual value is USD -23.1 M.<h3>Segment Revenue</h3><ul><li>Grant Revenue: $351,000 for the three and nine months ended September 30, 2025.</li></ul><h3>Operational Metrics</h3><ul><li>Research and Development Expenses: $12.6 million for the three months ended September 30, 2025, a decrease from $16.5 million for the same period in 2024. For the nine months ended September 30, 2025, R&amp;D expenses were $37.4 million, down from $51.8 million in 2024.</li><li>General and Administrative Expenses: $9.5 million for the three months ended September 30, 2025, down from $12.7 million in 2024. For the nine months ended September 30, 2025, G&amp;A expenses were $31.6 million, down from $40.7 million in 2024.</li><li>Manufacturing Services: $736,000 for the three months ended September 30, 2025, and $6.0 million for the nine months ended September 30, 2025.</li><li>Net Income (Loss) from Continuing Operations: $8.2 million for the three months ended September 30, 2025, compared to a loss of $51.0 million in 2024. For the nine months ended September 30, 2025, net income was $21.0 million, compared to a loss of $110.1 million in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Provided by (Used in) Operating Activities: $15.8 million provided for the nine months ended September 30, 2025, compared to $109.7 million used in 2024.</li><li>Net Cash (Used in) Provided by Investing Activities: - $223,000 used for the nine months ended September 30, 2025, compared to $142.4 million provided in 2024.</li><li>Net Cash Provided by (Used in) Financing Activities: $1.2 million provided for the nine months ended September 30, 2025, compared to - $92.1 million used in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Gain on Sale of VOWST Business: $27.2 million for the three months ended September 30, 2025, and $79.6 million for the nine months ended September 30, 2025.</li><li>Other Income (Expense), Net: $30.7 million of income for the three months ended September 30, 2025, compared to - $21.9 million of expense in 2024. For the nine months ended September 30, 2025, other income was $95.6 million, compared to - $17.7 million of expense in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company is progressing the development of SER-155, an investigational oral live biotherapeutic, and other pipeline programs. They are focusing on obtaining additional capital to support the SER-155 Phase 2 study and other development efforts.</li><li>Non-Core Business: The company completed the sale of its VOWST Business to SPN in September 2024 and is now focusing on advancing its remaining product candidates and exploring potential partnerships to support further development.</li><li>Priority: The company aims to secure additional funding to support ongoing operations and meet obligations, with a focus on advancing SER-155 and other live biotherapeutic candidates.</li></ul>

Seres Therap | 10-Q: FY2025 Q3 Revenue: USD 351 K